Literature DB >> 18797963

Pain levels within 24 hours after UFE: a comparison of morphine and fentanyl patient-controlled analgesia.

Hyun S Kim1, Gregory J Czuczman, Wanda K Nicholson, Luu D Pham, Jeffrey M Richman.   

Abstract

The purpose of this study was to assess the presence and severity of pain levels during 24 h after uterine fibroid embolization (UFE) for symptomatic leiomyomata and compare the effectiveness and adverse effects of morphine patient-controlled analgesia (PCA) versus fentanyl PCA. We carried out a prospective, nonrandomized study of 200 consecutive women who received UFE and morphine or fentanyl PCA after UFE. Pain perception levels were obtained on a 0-10 scale for the 24-h period after UFE. Linear regression methods were used to determine pain trends and differences in pain trends between two groups and the association between pain scores and patient covariates. One hundred eighty-five patients (92.5%) reported greater-than-baseline pain after UFE, and 198 patients (99%) required IV opioid PCA. One hundred thirty-six patients (68.0%) developed nausea during the 24-h period. Seventy-two patients (36%) received morphine PCA and 128 (64%) received fentanyl PCA, without demographic differences. The mean dose of morphine used was 33.8 +/- 26.7 mg, while the mean dose of fentanyl was 698.7 +/- 537.4 lg. Using this regimen, patients who received morphine PCA had significantly lower pain levels than those who received fentanyl PCA (p \ 0.0001). We conclude that patients develop pain requiring IV opioid PCA within 24 h after UFE. Morphine PCA is more effective in reducing post-uterine artery embolization pain than fentanyl PCA. Nausea is a significant adverse effect from opioid PCA.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18797963     DOI: 10.1007/s00270-008-9430-5

Source DB:  PubMed          Journal:  Cardiovasc Intervent Radiol        ISSN: 0174-1551            Impact factor:   2.740


  6 in total

1.  Four-dimensional transcatheter intra-arterial perfusion MR imaging before and after uterine artery embolization in the rabbit VX2 tumor model.

Authors:  Johnathan C Chung; Dingxin Wang; Robert J Lewandowski; Richard Tang; Howard B Chrisman; Robert L Vogelzang; Gayle E Woloschak; Andrew C Larson; Reed A Omary; Robert K Ryu
Journal:  J Magn Reson Imaging       Date:  2010-05       Impact factor: 4.813

2.  Lower Background Infusion of Oxycodone for Patient-Controlled Intravenous Analgesia, Combined with Ropivacaine Intercostal Nerve Block, in Patients Undergoing Thoracoscopic Lobectomy for Lung Cancer: A Randomized, Double-Blind, Controlled Clinical Trial.

Authors:  Yunxiao Zhang; Wanpu Yan; Yanyun Chen; Zhiyi Fan; Jiheng Chen
Journal:  Drug Des Devel Ther       Date:  2021-08-13       Impact factor: 4.162

3.  Intra-arterial lidocaine administration during uterine fibroid embolization to reduce the immediate postoperative pain: a prospective randomized study.

Authors:  Stevo Duvnjak; Poul Erik Andersen
Journal:  CVIR Endovasc       Date:  2020-02-10

4.  Retrospective Analysis of the Effect of Lidocaine Combined with Methylprednisolone on Pain Control After Uterine Artery Embolization.

Authors:  Yi Tang; Bin Lin; Yan-Ping Zhang; Ya-Nan Hu; Jian-Hui Zhang; Shao-Jie Wu; Yan-Feng Zhou; Sen-Lin Cai; Jie-Wei Luo; Wu Chi; Zhu-Ting Fang
Journal:  Front Surg       Date:  2022-04-19

5.  The efficacy of the time-scheduled decremental continuous infusion of fentanyl for postoperative patient-controlled analgesia after total intravenous anesthesia.

Authors:  Jong-Yeop Kim; Sung-Yong Park; Hyuk Soo Chang; Si-Kwon Nam; Sang-Kee Min
Journal:  Korean J Anesthesiol       Date:  2013-12-26

6.  Significance of changes in inflammatory parameters following uterine artery embolization in pre-menopausal females.

Authors:  Vasileios Souftas; Dorelia Deuteraiou; Xanthoula Anthoulaki; Anna Chalkidou; Anastasia Bothou; Fotini Gaidatzi; Grigorios Tsypsianis; Georgios Iatrakis; Stefanos Zervoudis; Dimitrios Souftas; Spyridon Michalopoulos; Theodosia Vogiatzaki; George Galazios; Nikolaos Nikolettos; Panagiotis Tsikouras
Journal:  Exp Ther Med       Date:  2020-04-09       Impact factor: 2.751

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.